文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic
侵权投诉

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study

Cell science Stain Solution (Cambridge Bio-were air-dried and migrated cells were Ltd, Cambridge, UK). Inserts placed bridge in UK). The plate was read at 560nm.Bioscience Extraction Ltd, Solution Cambridge, (Cam-The effect of GW856553X on cytokine release was determined. HUVEC (8x104per 10ng/ml 200mm2absence TNF-) αwere for 24 stimulated hours, with or Release of MCP-1, IL-6 and IL-8 were 0.01% or DMSO presence as of in the vehicle GW856553X control. measured scribed (3, 16).

by ELISA as previously de-Statistical analyses

Two-way evaluate ANOVA test sessing the dose and the time of treat-the clinical scoring was data, used as-to ment. One-way ANOVto evaluate the histological scoring data A test was used as a function of the dose. than 0.05 were considered to be statis-P-values less tically signi cant.

Results

Therapeutic effect of p38 MAPK inhibitor in acute and chronic relapsing CIA

The to acute CIA model GW856553X. establish the was rst used ly We dosing observed regime that for GW856553X intra-peritoneal administration dai-of thritis at (Fig. 1a). ameliorated This acute ar-GW856553X (the higher dosages effect was seen treated animals) while stabilisation was p<0.001 of versus10-20mg/kg vehicle-also cle-treated animals), at lower doses of achieved (p<0.001 versus vehi-0.8-4mg/kg, scores signi cantly observations were supported by reduced (p<0.001 in both cases). reducing These the joint GW856553X-treated mice, which was in ammation and destruction in evident across all joints (proximal and distal and GW856553X (Fig. 1b-h).

tibia-tarsal interphalangeal, joint) at rst all metatarsal doses of Having established the for dosing regime subsequently GW856553X in acute CIA, we GW856553X assessed arthritis. murine, Immunisation in a chronic the effect of of model of leads to rather disease than which bovine, mice with more collagen closely

From the day of onset of arthritis, mice were treated with GW856553X (0.8mg/kg, 4mg/kg or 20mg/Fig. 3. GW856553X reduces joint destruction in chronic CIA.

kg daily), vehicle alone or left untreated (n=5-7 per group). At the end of the study (day 29), animals were sacri ced and paws were sectioned for histological evaluation. Representative sections are shown as follows: ((proximal interphalangeal and distal interphalangeal joints). Statistical analysis was carried out by 1-way e) 20mg/kg GW856553X. (a) untreated, (b) vehicle-treated, (f) Results are mean (± SEM) histological score (metatarsal, tibia-tarsus, c) 0.8mg/kg GW856553X, (d) 4mg/kg GW856553X, ANOVA versus vehicle-treated mice: ***p<0.001.

Table I.From the day of onset of arthritis, mice were treated with GW856553X (0.8mg/kg, 4mg/kg GW856553X reduces joint destruction in chronic CIA

or 20mg/kg daily), vehicle alone or left untreated (n=5-7 per group). Haematoxylin and eosin sections were scored in a blinded fashion for pannus formation, synovitis, bone and cartilage erosion. Paws were assigned one of three grades: 0=normal; 1=moderate synovitis with some loss of cartilage; 2=extensive synovial hyperplasia, destruction of cartilage and some bone erosions. Data for number of distal interphalangeal joints scored are shown.

Treatment Histological score (number of affected joints)

Untreated Vehicle

1 9 0.8mg/kg GW856553X 0 8 64mg/kg GW856553X 8 6 5020mg/kg GW856553X

6 6

8 9

00

resembles intra-peritoneally from day 1 of arthri-RA. Animals were treated ameliorating For chronic CIA tis with either vehicle (1% DMSO plus 99% methyl cellulose) or GW856553X the example, on day 29 of (Fig. 2). at 0.33±0.21 clinical 20mg/kg doses of 0.8mg/kg, treated and scores arthritis, 0.00±0.00 were 0.29±0.18, to an untreated arthritic group of ani-once daily, and 4mg/kg compared or 20mg/kg with 0.8mg/kg, 4mg/kg for mice and mals. compared GW856553X effective GW856553X at all doses, was in found terms to be of

treated with vehicle (clinical score for

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

with 3.40±0.68 respectively, for animals untreated animals 2.90±0.64; Fig. 2a).

180

上一页第5页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email